Materiały źródłowe

• #1 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Factor V Leiden is a genetically inherited disorder which causes hypercoagulable state that accounts for 40-50% of cases of thrombophilia. […] Management of this disorder can be challenging due to the fact that the current treatment regimen can place the patient in a bleeding state with potential hazardous effects. […] Managing this disorder is challenging, because the current treatment regimen available can increase the patients chance of bleeding. […] Current management of factor V Leiden is based on the clinical manifestations in the patient. […] For patients with confirmed deep vein thrombosis or pulmonary embolism, anticoagulant therapy with subcutaneous low molecular-weight heparin, monitored IV, or subcutaneous unfractionated heparin or fondaparinux can be used. […] As in our patient, an initial course of intravenous unfractionated heparin or low molecular-weight heparin can be started followed by initiation of warfarin except when contraindicated.

• #2 Thromboembolic Disease and Factor V Leiden Defect | AAFP

  https://www.aafp.org/pubs/afp/issues/1998/0415/p1997.html

  Patients diagnosed with thromboembolic disease at a young age, or those who have a family history or recurrent episodes of the disease, typically undergo a battery of laboratory studies to identify inherited disorders of hemostasis. […] A single gene mutation in the coding for coagulation factor V, known as factor V Leiden, makes the activated form of factor V (Va) relatively resistant to degradation by activated protein C. […] Price and Ridker reviewed the literature on factor V Leiden to identify the prevalence and risks of thromboembolism associated with this mutation and suggest methods for diagnosis and treatment. […] Definitive diagnosis of the mutation requires the use of techniques based on polymerase chain reaction, although resistance to activated protein C may also be identified using relatively simple plasma testing.

• #3 Factor V Leiden thrombophilia | Genetics in Medicine

  https://www.nature.com/articles/gim920112

  Factor V Leiden is a genetic disorder characterized by a poor anticoagulant response to activated Protein C and an increased risk for venous thromboembolism. […] The first acute thrombosis is treated according to standard guidelines. Decisions regarding the optimal duration of anticoagulation are based on an individualized assessment of the risks for venous thromboembolism recurrence and anticoagulant-related bleeding. […] In the absence of a history of thrombosis, long-term anticoagulation is not routinely recommended for asymptomatic Factor V Leiden heterozygotes, although prophylactic anticoagulation may be considered in high-risk clinical settings. […] The management of individuals with Factor V Leiden depends on the clinical circumstances. The first acute VTE should be treated according to standard guidelines with a course of low molecular weight heparin (LMWH) or intravenous unfractionated heparin. Warfarin is started concurrently with LMWH (except during pregnancy) and monitored with the international normalized ratio (INR).

• #4 Factor V Leiden – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/factor-v-leiden/symptoms-causes/syc-20372423

  If you have factor V Leiden and have developed blood clots, anticoagulant medications can lessen your risk of developing additional blood clots and help you avoid potentially serious complications. […] Factor V Leiden can cause blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism). These blood clots can be life-threatening.

• #5 Factor V Leiden Mutation | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/21577

  Management of venous thromboembolism in people with factor V Leiden mutation is the same as that of the general population, and factor V Leiden mutation will not affect the decision about which anticoagulant one should use. The choice of anticoagulant is based on some factors like patient preference, adherence to therapy, the severity of thrombosis, and drug interactions. […] Generally, direct oral anticoagulants (DOAC) are usually used for patients with typical VTE presentations. Warfarin is preferred if there is a concern about adherence or for those who present with a submassive/massive pulmonary embolism who would benefit from maintaining INR at the high end of the therapeutic range. […] The duration of VTE treatment is not different between factor V Leiden and the general population, and it depends on the risk of recurrent VTE. It is highly recommended that one continue indefinite anticoagulation for unprovoked, life-threatening venous thromboembolism, VTE at an unusual location or if it is recurrent. […] Individuals with factor V Leiden homozygous mutation who undergo surgery should be treated as a high-risk group and receive prophylactic anticoagulation.

• #6 Factor V Leiden | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/factor-v-leiden?lang=us

  The presence of factor V Leiden does not change anticoagulant management in patients with thromboembolism, and there is no role for prophylactic anticoagulation for patients who are homozygous or heterozygous to the factor V Leiden allele 1.

• #7 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Factor V Leiden is a genetically inherited disorder which causes hypercoagulable state that accounts for 40-50% of cases of thrombophilia. […] Management of this disorder can be challenging due to the fact that the current treatment regimen can place the patient in a bleeding state with potential hazardous effects. […] Managing this disorder is challenging, because the current treatment regimen available can increase the patients chance of bleeding. […] Current management of factor V Leiden is based on the clinical manifestations in the patient. […] For patients with confirmed deep vein thrombosis or pulmonary embolism, anticoagulant therapy with subcutaneous low molecular-weight heparin, monitored IV, or subcutaneous unfractionated heparin or fondaparinux can be used. […] As in our patient, an initial course of intravenous unfractionated heparin or low molecular-weight heparin can be started followed by initiation of warfarin except when contraindicated.

• #8 Factor V Leiden Thrombophilia: Genetics, Symptoms, and Treatment

  https://www.healthline.com/health/factor-v-leiden-thrombophilia

  This condition can often be managed effectively with appropriate medical interventions, helping to prevent and treat blood clots. […] Treatment options for Factor V Leiden thrombophilia focus on managing and preventing blood clots. The approach varies depending on whether the person has experienced a clot or not, and whether they have other risk factors. […] When managing a clot due to Factor V Leiden thrombophilia, the primary goal is to dissolve the clot and prevent further clotting. […] Treatment begins with anticoagulants to quickly address the clot and reduce the risk of new ones. Initially, injectable anticoagulants such as heparin or low molecular weight heparin are used for their rapid effect. […] After stabilizing the situation, patients typically transition to oral anticoagulants like warfarin or direct oral anticoagulants, which are used for longer-term management.

• #9 Factor V Leiden: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/17896-factor-v-leiden

  The factor V Leiden mutation itself doesn’t have any specific treatment. But when a person is diagnosed with an acute deep vein thrombosis (DVT) or pulmonary embolism (PE), treatment with anticoagulants (blood thinners) will be necessary and should be started as soon as possible. Depending on the severity of symptoms, other treatments may be necessary as well. Often, those treatments will require hospitalization. […] Individuals who happen to know that they have factor V Leiden but have never had blood clots don’t have to be prescribed any blood thinners. But it’s important that these individuals discuss with their doctors what they should be aware of and what they can do to minimize the risk of DVT or PE. Some issues that can be discussed with your doctor include: […] Effective measures to eliminate or reduce other risk factors for DVT or PE, such as smoking cessation, weight loss and having a more active lifestyle.

• #10 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Factor V Leiden is a genetically inherited disorder which causes hypercoagulable state that accounts for 40-50% of cases of thrombophilia. […] Management of this disorder can be challenging due to the fact that the current treatment regimen can place the patient in a bleeding state with potential hazardous effects. […] Managing this disorder is challenging, because the current treatment regimen available can increase the patients chance of bleeding. […] Current management of factor V Leiden is based on the clinical manifestations in the patient. […] For patients with confirmed deep vein thrombosis or pulmonary embolism, anticoagulant therapy with subcutaneous low molecular-weight heparin, monitored IV, or subcutaneous unfractionated heparin or fondaparinux can be used. […] As in our patient, an initial course of intravenous unfractionated heparin or low molecular-weight heparin can be started followed by initiation of warfarin except when contraindicated.

• #11 Factor V Leiden Thrombophilia: Genetics, Symptoms, and Treatment

  https://www.healthline.com/health/factor-v-leiden-thrombophilia

  This condition can often be managed effectively with appropriate medical interventions, helping to prevent and treat blood clots. […] Treatment options for Factor V Leiden thrombophilia focus on managing and preventing blood clots. The approach varies depending on whether the person has experienced a clot or not, and whether they have other risk factors. […] When managing a clot due to Factor V Leiden thrombophilia, the primary goal is to dissolve the clot and prevent further clotting. […] Treatment begins with anticoagulants to quickly address the clot and reduce the risk of new ones. Initially, injectable anticoagulants such as heparin or low molecular weight heparin are used for their rapid effect. […] After stabilizing the situation, patients typically transition to oral anticoagulants like warfarin or direct oral anticoagulants, which are used for longer-term management.

• #12 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Factor V Leiden is a genetically inherited disorder which causes hypercoagulable state that accounts for 40-50% of cases of thrombophilia. […] Management of this disorder can be challenging due to the fact that the current treatment regimen can place the patient in a bleeding state with potential hazardous effects. […] Managing this disorder is challenging, because the current treatment regimen available can increase the patients chance of bleeding. […] Current management of factor V Leiden is based on the clinical manifestations in the patient. […] For patients with confirmed deep vein thrombosis or pulmonary embolism, anticoagulant therapy with subcutaneous low molecular-weight heparin, monitored IV, or subcutaneous unfractionated heparin or fondaparinux can be used. […] As in our patient, an initial course of intravenous unfractionated heparin or low molecular-weight heparin can be started followed by initiation of warfarin except when contraindicated.

• #13 Factor V Leiden: Symptoms, Cause, Diagnosis, and Treatment

  https://www.webmd.com/dvt/factor-v-leiden

  People who have this mutation are born with it. One or both of your parents passed it on to you. […] If you need treatment, you’ll take a blood-thinning drug to help prevent clots from forming. Doctors call these medicines anticoagulants. Two of the most common are: […] Heparin. This medication works quickly. Your doctor can inject it into a vein (intravenously) or under your skin (subcutaneously). Or you may be able to give yourself the injection. This drug is safe for pregnant women. Heparin may have side effects including excess bleeding and allergic reaction. There’s no standard dose, so you’ll need to have blood tests that will help your doctor figure out how much is right for you. You may need to adjust the dose from time to time, too. […] Warfarin (Coumadin, Jantoven). You take this medication as a pill. There’s no standard dose for it, either, so as with heparin, you’ll need to see the doctor often for tests and adjustments. It can cause bleeding, and it isn’t safe for pregnant women, especially the first trimester. Tell your doctor about anything else you’re taking when you start warfarin. It can affect the way other drugs and herbs work.

• #14 Factor V Leiden Thrombophilia – DoveMed

  https://www.dovemed.com/diseases-conditions/factor-v-leiden-thrombophilia

  The usual treatment options for abnormal clot formation are the use of anticoagulants such as heparin, warfarin, rivaroxaban, etc. […] Blood thinning medicines are generally administered to treat individuals with active abnormal blood clot formation. The treatment options include: Heparin (or low molecular weight heparin), administered through the vein, or under the skin; Warfarin (oral medication) may also be given, except during pregnancy, as it may cause birth defects; Generally, the initial treatment given is a combination of warfarin and heparin, followed by warfarin alone; Other medications that may be given include enoxaparin, dalteparin, dabigatran, and rivaroxaban. […] When an individual is taking anticoagulant medication, he/she should be monitored for side effects (bleeding) by the healthcare provider including by using periodic blood tests.

• #15 Review of Factor V Leiden Thrombophilia

  https://www.uspharmacist.com/article/review-of-factor-v-leiden-thrombophilia

  Once the diagnosis of DVT in the left lower extremity was made, the patient was treated with rivaroxaban (Xarelto). He was told that since this was an unprovoked DVT and he was heterozygous for factor V Leiden, which is associated with activated protein C resistance, he was at significant risk for future venous thrombosis and would need lifetime anticoagulation therapy. […] Current oral pharmacotherapy options available for coagulopathy due to factor V Leiden include vitamin K antagonists and direct oral anticoagulants (DOACs) such as direct thrombin inhibitors and factor Xa inhibitors.

• #16 Factor V Leiden: Symptoms, Cause, Diagnosis, and Treatment

  https://www.webmd.com/dvt/factor-v-leiden

  People who have this mutation are born with it. One or both of your parents passed it on to you. […] If you need treatment, you’ll take a blood-thinning drug to help prevent clots from forming. Doctors call these medicines anticoagulants. Two of the most common are: […] Heparin. This medication works quickly. Your doctor can inject it into a vein (intravenously) or under your skin (subcutaneously). Or you may be able to give yourself the injection. This drug is safe for pregnant women. Heparin may have side effects including excess bleeding and allergic reaction. There’s no standard dose, so you’ll need to have blood tests that will help your doctor figure out how much is right for you. You may need to adjust the dose from time to time, too. […] Warfarin (Coumadin, Jantoven). You take this medication as a pill. There’s no standard dose for it, either, so as with heparin, you’ll need to see the doctor often for tests and adjustments. It can cause bleeding, and it isn’t safe for pregnant women, especially the first trimester. Tell your doctor about anything else you’re taking when you start warfarin. It can affect the way other drugs and herbs work.

• #17 Factor V Leiden: Symptoms, Cause, Diagnosis, and Treatment

  https://www.webmd.com/dvt/factor-v-leiden

  Or you might take anticoagulant pills that don’t need testing and adjustments but might make you more likely to bleed. These include: Apixaban (Eliquis), Dabigatran (Pradaxa), Rivaroxaban (Xarelto). […] Since there’s no cure for these genetic mutations, the goal is to lower your chance of having risky blood clots while still letting your body make the clots that it truly needs.

• #18 Review of Factor V Leiden Thrombophilia

  https://www.uspharmacist.com/article/review-of-factor-v-leiden-thrombophilia

  Once the diagnosis of DVT in the left lower extremity was made, the patient was treated with rivaroxaban (Xarelto). He was told that since this was an unprovoked DVT and he was heterozygous for factor V Leiden, which is associated with activated protein C resistance, he was at significant risk for future venous thrombosis and would need lifetime anticoagulation therapy. […] Current oral pharmacotherapy options available for coagulopathy due to factor V Leiden include vitamin K antagonists and direct oral anticoagulants (DOACs) such as direct thrombin inhibitors and factor Xa inhibitors.

• #19 Factor V Leiden Mutation | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/21577

  Management of venous thromboembolism in people with factor V Leiden mutation is the same as that of the general population, and factor V Leiden mutation will not affect the decision about which anticoagulant one should use. The choice of anticoagulant is based on some factors like patient preference, adherence to therapy, the severity of thrombosis, and drug interactions. […] Generally, direct oral anticoagulants (DOAC) are usually used for patients with typical VTE presentations. Warfarin is preferred if there is a concern about adherence or for those who present with a submassive/massive pulmonary embolism who would benefit from maintaining INR at the high end of the therapeutic range. […] The duration of VTE treatment is not different between factor V Leiden and the general population, and it depends on the risk of recurrent VTE. It is highly recommended that one continue indefinite anticoagulation for unprovoked, life-threatening venous thromboembolism, VTE at an unusual location or if it is recurrent. […] Individuals with factor V Leiden homozygous mutation who undergo surgery should be treated as a high-risk group and receive prophylactic anticoagulation.

• #20 Factor V Leiden Thrombophilia: Genetics, Symptoms, and Treatment

  https://www.healthline.com/health/factor-v-leiden-thrombophilia

  For severe cases, thrombolytics, which are medications that dissolve clots, may be administered, but these carry a higher risk of bleeding and are reserved for critical situations. […] The duration of anticoagulant therapy usually spans from 3 to 6 months, but in some cases, extended treatment may be required, particularly if the patient has recurrent clots or high risk factors. […] Pregnant people with Factor V Leiden thrombophilia, particularly those with a history of blood clots or those who are homozygous for the gene (have two copies, one from each parent), may need to use anticoagulants both during and after pregnancy to reduce the risk of clotting. […] Those with a history of blood clots should avoid estrogen-containing birth control and HRT methods. Estrogen can increase the risk of clot formation, so it’s important to choose alternative methods.

• #21 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Agents/circumstances to avoid: Women with a history of VTE who are heterozygous for the factor V Leiden variant and women homozygous for the factor V Leiden variant with or without prior VTE should avoid estrogen-containing contraception and HRT. […] Pregnancy management: Women with thrombophilia should undergo individualized risk assessment. In women heterozygous for the factor V Leiden variant, antepartum prophylactic anticoagulation is not recommended for prevention of the first VTE. In homozygous and double heterozygous women (factor V Leiden and F2 20210GA variants), antepartum and postpartum prophylactic anticoagulation is suggested to prevent a first VTE. […] The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors.

• #22 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Indefinite anticoagulation is recommended for individuals with a first or recurrent unprovoked proximal DVT of the leg and a high risk of recurrence due to risk factors such as cancer, combined thrombophilia, or homozygosity for the factor V Leiden variant. […] Treatment of VTE in Children: The treatment of acute VTE is not influenced by identification of a factor V Leiden variant. Children with a first VTE should receive initial treatment with either unfractionated heparin or LMWH for at least five days. […] In children with a factor V Leiden variant, the duration of anticoagulation following VTE may include indefinite anticoagulation or intermittent anticoagulation in high-risk situations after considering the risk of side effects of anticoagulation (e.g., major bleeding), the risk of recurrent VTE, and the preference of the affected individual.

• #23 Factor V Leiden Thrombophilia: Genetics, Symptoms, and Treatment

  https://www.healthline.com/health/factor-v-leiden-thrombophilia

  For severe cases, thrombolytics, which are medications that dissolve clots, may be administered, but these carry a higher risk of bleeding and are reserved for critical situations. […] The duration of anticoagulant therapy usually spans from 3 to 6 months, but in some cases, extended treatment may be required, particularly if the patient has recurrent clots or high risk factors. […] Pregnant people with Factor V Leiden thrombophilia, particularly those with a history of blood clots or those who are homozygous for the gene (have two copies, one from each parent), may need to use anticoagulants both during and after pregnancy to reduce the risk of clotting. […] Those with a history of blood clots should avoid estrogen-containing birth control and HRT methods. Estrogen can increase the risk of clot formation, so it’s important to choose alternative methods.

• #24 Factor V Leiden Information – Milton Keynes University Hospital

  https://www.mkuh.nhs.uk/patient-information-leaflet/factor-v-leiden-information

  People with Factor V Leiden do not need treatment unless there is a blood clot. In this case the doctor will prescribe medication (anticoagulant) to make the blood take longer to clot. Treatment will usually last 3-6 months but may be longer depending on the individual circumstances. […] If you require surgery or are immobile/bed bound tell your doctor you carry the Factor V Leiden gene as treatment to prevent thrombosis is likely to be recommended. […] If you have had a clot it is likely you will have low molecular weight heparin injections throughout pregnancy and the 6 weeks after birth. It is therefore important that you tell your doctor/midwife early that you are pregnant, or ideally before. […] If you are not on treatment it is important that you let your doctor know your Factor V Leiden status if you are hospitalised.

• #25 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Indefinite anticoagulation is recommended for individuals with a first or recurrent unprovoked proximal DVT of the leg and a high risk of recurrence due to risk factors such as cancer, combined thrombophilia, or homozygosity for the factor V Leiden variant. […] Treatment of VTE in Children: The treatment of acute VTE is not influenced by identification of a factor V Leiden variant. Children with a first VTE should receive initial treatment with either unfractionated heparin or LMWH for at least five days. […] In children with a factor V Leiden variant, the duration of anticoagulation following VTE may include indefinite anticoagulation or intermittent anticoagulation in high-risk situations after considering the risk of side effects of anticoagulation (e.g., major bleeding), the risk of recurrent VTE, and the preference of the affected individual.

• #26 Factor V Leiden Mutation | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/21577

  Management of venous thromboembolism in people with factor V Leiden mutation is the same as that of the general population, and factor V Leiden mutation will not affect the decision about which anticoagulant one should use. The choice of anticoagulant is based on some factors like patient preference, adherence to therapy, the severity of thrombosis, and drug interactions. […] Generally, direct oral anticoagulants (DOAC) are usually used for patients with typical VTE presentations. Warfarin is preferred if there is a concern about adherence or for those who present with a submassive/massive pulmonary embolism who would benefit from maintaining INR at the high end of the therapeutic range. […] The duration of VTE treatment is not different between factor V Leiden and the general population, and it depends on the risk of recurrent VTE. It is highly recommended that one continue indefinite anticoagulation for unprovoked, life-threatening venous thromboembolism, VTE at an unusual location or if it is recurrent. […] Individuals with factor V Leiden homozygous mutation who undergo surgery should be treated as a high-risk group and receive prophylactic anticoagulation.

• #27 Review of Factor V Leiden Thrombophilia

  https://www.uspharmacist.com/article/review-of-factor-v-leiden-thrombophilia

  Factor V Leiden thrombophilia is a genetic disorder that may increase a patients risk of developing a venous thromboembolism (VTE). Current management strategies involve the use of pharmacotherapy, when indicated, in the event of deep venous thrombosis or pulmonary embolism. Treatment guidelines have specific recommendations regarding the use of oral anticoagulant therapy for the treatment and prevention of VTE events. Pharmacotherapy options include vitamin K antagonists or direct oral anticoagulants, such as direct thrombin inhibitors, and factor Xa inhibitors. […] The treatment guidelines are not specific on the use of pharmacotherapy unless the patient has experienced an episode of VTE. […] Current guidelines do not address empiric therapy with anticoagulants for those individuals who have not yet experienced thrombosis. The American College of Chest Physicians recommends anticoagulant therapy for VTE events that are provoked or unprovoked DVTs and PEs. The use of anticoagulant therapy for 3 months is recommended in the following instances: patients who experience proximal DVT of the leg or PE that is provoked by surgery; proximal DVT of the leg or PE provoked by a nonsurgical transient risk factor; patients who experience isolated distal DVT of the leg provoked by surgery or a nonsurgical transient risk factor; and in patients with an unprovoked DVT of the leg (isolated distal or proximal) or PE. In patients whose first VTE is unprovoked proximal DVT of the leg or PE and who have a low or moderate bleeding risk, the recommendation is extended anticoagulant therapy (no scheduled stop date); for those who have a high bleeding risk, the recommendation is 3 months of therapy.

• #28 Factor V Leiden: Signs, Symptoms and Treatment

  https://www.nationwidechildrens.org/conditions/factor-v-leiden-2

  Most people with Factor V Leiden do not develop blood clots and do not need treatment. […] If blood clots become an issue, „blood-thinning” medicines (like Enoxaparin) can be used. This will halt growth of the clot and reduce the risk of future clots.

• #29 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Treatment of manifestations: The first acute venous thrombosis is treated according to current guidelines. The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. […] Prevention of primary manifestations: In the absence of a history of thrombosis, long-term prophylactic anticoagulation is not routinely recommended for asymptomatic factor V Leiden variant heterozygotes. A short course of prophylactic anticoagulation when transient risk factors are present may prevent initial thrombosis in heterozygotes. […] Surveillance: Periodic reevaluation of individuals on long-term anticoagulation to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.

• #30 Factor V (Five) Leiden Mutation | Fact Sheets

  https://www.melbournehaematology.com.au/fact-sheets/factor-v-five-leiden-mutation.html

  Is there any treatment for Factor V Leiden? No treatment to change genes is currently available. Most people who have Factor V Leiden mutation do not need any treatment but need to be careful at times when the risk of getting a blood clot may be increased (e.g. after surgery, during long flights etc). […] Sometimes people with the Factor V Leiden mutation may need to go on blood thinning medication to reduce the risk of developing blood clots. This will depend on lots of other factors including a past medical history of clots or a family history of blood clots.

• #31 Factor V Leiden: all the answers – Breda Genetics srl

  https://bredagenetics.com/factor-v-leiden-all-the-answers/

  In asymptomatic patients (i.e. who have never had an episode of venous thrombosis), long-term prophylactic anticoagulant therapy is not indicated, but only short-term therapy in the event of an exposure to circumstantial risk factors (see above). […] Women heterozygous for the Leiden variant with a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] women homozygous for the Leiden variant with or without a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] for asymptomatic heterozygous women it would still be advisable to evaluate alternative forms of contraception or control of menopausal symptoms. However, for asymptomatic heterozygous women who still prefer oral contraceptive therapy, it would be best to avoid third generation progestogens or other types of progestogens that confer a high thrombotic risk. For asymptomatic heterozygous women wishing to undergo hormone replacement therapy to control particularly severe menopausal symptoms, oral hormone replacement therapy should still be avoided.

• #32 Factor V Leiden: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/17896-factor-v-leiden

  The factor V Leiden mutation itself doesn’t have any specific treatment. But when a person is diagnosed with an acute deep vein thrombosis (DVT) or pulmonary embolism (PE), treatment with anticoagulants (blood thinners) will be necessary and should be started as soon as possible. Depending on the severity of symptoms, other treatments may be necessary as well. Often, those treatments will require hospitalization. […] Individuals who happen to know that they have factor V Leiden but have never had blood clots don’t have to be prescribed any blood thinners. But it’s important that these individuals discuss with their doctors what they should be aware of and what they can do to minimize the risk of DVT or PE. Some issues that can be discussed with your doctor include: […] Effective measures to eliminate or reduce other risk factors for DVT or PE, such as smoking cessation, weight loss and having a more active lifestyle.

• #33 About Factor V Leiden Thrombophilia

  https://www.genome.gov/Genetic-Disorders/Factor-V-Leiden-Thrombophilia

  The management of individuals with factor V Leiden depends on the clinical circumstances. People with factor V Leiden who have had a DVT or PE are usually treated with blood thinners, or anticoagulants. Anticoagulants such as heparin are given for varying amounts of time depending on the person’s situation. It is not usually recommended that people with factor V Leiden be treated lifelong with anticoagulants if they have had only one DVT or PE, unless there are additional risk factors present. […] In general, individuals who have factor V Leiden but have never had a blood clot are not routinely treated with an anticoagulant. Rather, these individuals are counseled about reducing or eliminating other factors that may add to one’s risk of developing a clot in the future. In addition, these individuals may require temporary treatment with an anticoagulant during periods of particularly high risk, such as major surgery. Factor V Leiden increases the risk of developing a DVT during pregnancy by about seven-fold. Women with factor V Leiden who are planning pregnancy should discuss this with their obstetrician and/or hematologist. Most women with factor V Leiden have normal pregnancies and only require close follow-up during pregnancy. For those with a history of DVT or PE, treatment with an anticoagulant during a subsequent pregnancy can prevent recurrent problems.

• #34 Factor V Leiden – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/factor-v-leiden/diagnosis-treatment/drc-20372428

  Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery. […] For factor V Leiden, some basic questions to ask your doctor include: Does my factor V Leiden need to be treated? Do I need to take medication to prevent additional blood clots?

• #35 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Treatment of manifestations: The first acute venous thrombosis is treated according to current guidelines. The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. […] Prevention of primary manifestations: In the absence of a history of thrombosis, long-term prophylactic anticoagulation is not routinely recommended for asymptomatic factor V Leiden variant heterozygotes. A short course of prophylactic anticoagulation when transient risk factors are present may prevent initial thrombosis in heterozygotes. […] Surveillance: Periodic reevaluation of individuals on long-term anticoagulation to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.

• #36 Factor V Leiden

  https://www.mymlc.com/health-information/diseases-and-conditions/f/factor-v-leiden2/

  If you have factor V Leiden and have developed blood clots, anticoagulant medications can lessen your risk of developing additional blood clots and help you avoid potentially serious complications. […] Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery.

• #37 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Treatment of manifestations: The first acute venous thrombosis is treated according to current guidelines. The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. […] Prevention of primary manifestations: In the absence of a history of thrombosis, long-term prophylactic anticoagulation is not routinely recommended for asymptomatic factor V Leiden variant heterozygotes. A short course of prophylactic anticoagulation when transient risk factors are present may prevent initial thrombosis in heterozygotes. […] Surveillance: Periodic reevaluation of individuals on long-term anticoagulation to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.

• #38 Factor V Leiden Information – Milton Keynes University Hospital

  https://www.mkuh.nhs.uk/patient-information-leaflet/factor-v-leiden-information

  People with Factor V Leiden do not need treatment unless there is a blood clot. In this case the doctor will prescribe medication (anticoagulant) to make the blood take longer to clot. Treatment will usually last 3-6 months but may be longer depending on the individual circumstances. […] If you require surgery or are immobile/bed bound tell your doctor you carry the Factor V Leiden gene as treatment to prevent thrombosis is likely to be recommended. […] If you have had a clot it is likely you will have low molecular weight heparin injections throughout pregnancy and the 6 weeks after birth. It is therefore important that you tell your doctor/midwife early that you are pregnant, or ideally before. […] If you are not on treatment it is important that you let your doctor know your Factor V Leiden status if you are hospitalised.

• #39 Factor V (Five) Leiden Mutation | Fact Sheets

  https://www.melbournehaematology.com.au/fact-sheets/factor-v-five-leiden-mutation.html

  Is there any treatment for Factor V Leiden? No treatment to change genes is currently available. Most people who have Factor V Leiden mutation do not need any treatment but need to be careful at times when the risk of getting a blood clot may be increased (e.g. after surgery, during long flights etc). […] Sometimes people with the Factor V Leiden mutation may need to go on blood thinning medication to reduce the risk of developing blood clots. This will depend on lots of other factors including a past medical history of clots or a family history of blood clots.

• #40 Factor V Leiden Mutation | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/21577

  Management of venous thromboembolism in people with factor V Leiden mutation is the same as that of the general population, and factor V Leiden mutation will not affect the decision about which anticoagulant one should use. The choice of anticoagulant is based on some factors like patient preference, adherence to therapy, the severity of thrombosis, and drug interactions. […] Generally, direct oral anticoagulants (DOAC) are usually used for patients with typical VTE presentations. Warfarin is preferred if there is a concern about adherence or for those who present with a submassive/massive pulmonary embolism who would benefit from maintaining INR at the high end of the therapeutic range. […] The duration of VTE treatment is not different between factor V Leiden and the general population, and it depends on the risk of recurrent VTE. It is highly recommended that one continue indefinite anticoagulation for unprovoked, life-threatening venous thromboembolism, VTE at an unusual location or if it is recurrent. […] Individuals with factor V Leiden homozygous mutation who undergo surgery should be treated as a high-risk group and receive prophylactic anticoagulation.

• #41 Factor V Leiden – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/factor-v-leiden/diagnosis-treatment/drc-20372428

  Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery. […] For factor V Leiden, some basic questions to ask your doctor include: Does my factor V Leiden need to be treated? Do I need to take medication to prevent additional blood clots?

• #42 Factor V Leiden

  https://www.mymlc.com/health-information/diseases-and-conditions/f/factor-v-leiden2/

  If you have factor V Leiden and have developed blood clots, anticoagulant medications can lessen your risk of developing additional blood clots and help you avoid potentially serious complications. […] Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery.

• #43 Factor V Leiden | The Foundation to Advance Vascular Cures

  https://www.vascularcures.org/factor-v-leiden

  Factor V Leiden can be confirmed by a blood test and by genetic testing. A health care provider may test you for factor V Leiden if you have had abnormal clotting or have a strong family history of clotting problems. […] Clinicians or providers may prescribe blood-thinners to help prevent blood clots for people who are considered high risk. However, this type of medication may not be needed if people with factor V Leiden have never experienced abnormal blood clots. […] Your provider might suggest other ways to prevent blood clots: Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for regular walks.

• #44 Factor V Leiden – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/factor-v-leiden/diagnosis-treatment/drc-20372428

  Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery. […] For factor V Leiden, some basic questions to ask your doctor include: Does my factor V Leiden need to be treated? Do I need to take medication to prevent additional blood clots?

• #45 Factor V Leiden

  https://www.mymlc.com/health-information/diseases-and-conditions/f/factor-v-leiden2/

  If you have factor V Leiden and have developed blood clots, anticoagulant medications can lessen your risk of developing additional blood clots and help you avoid potentially serious complications. […] Doctors generally prescribe blood-thinning medications to treat people who develop abnormal blood clots. This type of medicine usually isn’t needed for people who have the factor V Leiden mutation but who have not experienced abnormal blood clots. […] However, your doctor might suggest that you take extra precautions to prevent blood clots if you have the factor V Leiden mutation and are going to have surgery. These precautions might include: A short course of blood thinners, Leg wraps that inflate and deflate to keep blood moving in your legs, Compression stockings, Going for walks soon after surgery.

• #46 Factor V Leiden: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/17896-factor-v-leiden

  The factor V Leiden mutation itself doesn’t have any specific treatment. But when a person is diagnosed with an acute deep vein thrombosis (DVT) or pulmonary embolism (PE), treatment with anticoagulants (blood thinners) will be necessary and should be started as soon as possible. Depending on the severity of symptoms, other treatments may be necessary as well. Often, those treatments will require hospitalization. […] Individuals who happen to know that they have factor V Leiden but have never had blood clots don’t have to be prescribed any blood thinners. But it’s important that these individuals discuss with their doctors what they should be aware of and what they can do to minimize the risk of DVT or PE. Some issues that can be discussed with your doctor include: […] Effective measures to eliminate or reduce other risk factors for DVT or PE, such as smoking cessation, weight loss and having a more active lifestyle.

• #47 Azthena logo with the word Azthena

  https://www.news-medical.net/health/What-is-Factor-V-Leiden.aspx

  There is no treatment that will cure factor V Leiden. Patients with factor V Leiden who have had deep vein thrombosis or a pulmonary embolism will be treated with anticoagulants (also called blood-thinners), which are medications that prevent blood clots by interrupting the clotting process. Lifelong anticoagulation is not recommended, however, in the absence of additional risk factors. […] Instead of prolonged anticoagulation, lifestyle changes can be made to reduce a persons overall risk of developing DVT or PE as a result of factor V Leiden. Such measures include: […] Maintaining a good weight for the height and sex […] Regular exercise […] cessation of smoking […] Avoiding long periods of immobility […] Controlling conditions like diabetes or high cholesterol.

• #48 Factor V Leiden mutation

  https://www.aboutkidshealth.ca/factor-v-leiden-mutation

  Although there is no direct treatment for the FVL mutation, preventative measures like exercise, a healthy diet, and avoiding smoking and/or alcohol consumption, are some ways that the risk for developing blood clots can be reduced. […] There is no direct treatment for FVL disorder. Instead, the goal of management is to minimize the risk of getting a blood clot in the first place. […] The following measures may be taken to prevent blood clots: Maintain a healthy diet. Talk to your child’s health-care team before changing your child’s diet and follow Canada’s Food Guide where applicable. Any irregular weight gain can contribute to the poor circulation of blood in the veins, increasing the risk of blood clots. […] Smoking and binge drinking or excessive alcohol consumption should be avoided.

• #49 Azthena logo with the word Azthena

  https://www.news-medical.net/health/What-is-Factor-V-Leiden.aspx

  There is no treatment that will cure factor V Leiden. Patients with factor V Leiden who have had deep vein thrombosis or a pulmonary embolism will be treated with anticoagulants (also called blood-thinners), which are medications that prevent blood clots by interrupting the clotting process. Lifelong anticoagulation is not recommended, however, in the absence of additional risk factors. […] Instead of prolonged anticoagulation, lifestyle changes can be made to reduce a persons overall risk of developing DVT or PE as a result of factor V Leiden. Such measures include: […] Maintaining a good weight for the height and sex […] Regular exercise […] cessation of smoking […] Avoiding long periods of immobility […] Controlling conditions like diabetes or high cholesterol.

• #50 Factor V Leiden mutation

  https://www.aboutkidshealth.ca/factor-v-leiden-mutation

  Although there is no direct treatment for the FVL mutation, preventative measures like exercise, a healthy diet, and avoiding smoking and/or alcohol consumption, are some ways that the risk for developing blood clots can be reduced. […] There is no direct treatment for FVL disorder. Instead, the goal of management is to minimize the risk of getting a blood clot in the first place. […] The following measures may be taken to prevent blood clots: Maintain a healthy diet. Talk to your child’s health-care team before changing your child’s diet and follow Canada’s Food Guide where applicable. Any irregular weight gain can contribute to the poor circulation of blood in the veins, increasing the risk of blood clots. […] Smoking and binge drinking or excessive alcohol consumption should be avoided.

• #51 Factor V Leiden mutation

  https://www.aboutkidshealth.ca/factor-v-leiden-mutation

  When travelling, encourage your child to walk around whenever possible. Decreased circulation of blood flow can increase the risk for blood clots. […] Encourage your child to get regular physical activity. Children and youth typically need at least 60 minutes of moderate-to-vigorous intensity physical activity every day. […] If a child with FVL needs to take hormonal therapy (e.g., birth control pills), talk to a gynecologist about how they can be safely taken, in order to help reduce the risk of blood clots.

• #52

  https://myhealth.alberta.ca/Health/aftercareinformation/pages/conditions.aspx?hwid=uf8198

  Many things can increase the chance of blood clots, including smoking and not being able to walk or move around for a long time. Your treatment may include a medicine (called a blood thinner) that prevents blood clots. […] If you take a blood thinner, be sure you get instructions about how to take your medicine safely. Blood thinners can cause serious bleeding problems. […] Check with your doctor about whether you should use hormone forms of birth control or hormone therapy. These may increase your risk of blood clots. […] If you need help quitting, talk to your doctor about stop-smoking programs and medicines. These can increase your chances of quitting for good.

• #53 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Agents/circumstances to avoid: Women with a history of VTE who are heterozygous for the factor V Leiden variant and women homozygous for the factor V Leiden variant with or without prior VTE should avoid estrogen-containing contraception and HRT. […] Pregnancy management: Women with thrombophilia should undergo individualized risk assessment. In women heterozygous for the factor V Leiden variant, antepartum prophylactic anticoagulation is not recommended for prevention of the first VTE. In homozygous and double heterozygous women (factor V Leiden and F2 20210GA variants), antepartum and postpartum prophylactic anticoagulation is suggested to prevent a first VTE. […] The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors.

• #54 Factor V Leiden: all the answers – Breda Genetics srl

  https://bredagenetics.com/factor-v-leiden-all-the-answers/

  In asymptomatic patients (i.e. who have never had an episode of venous thrombosis), long-term prophylactic anticoagulant therapy is not indicated, but only short-term therapy in the event of an exposure to circumstantial risk factors (see above). […] Women heterozygous for the Leiden variant with a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] women homozygous for the Leiden variant with or without a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] for asymptomatic heterozygous women it would still be advisable to evaluate alternative forms of contraception or control of menopausal symptoms. However, for asymptomatic heterozygous women who still prefer oral contraceptive therapy, it would be best to avoid third generation progestogens or other types of progestogens that confer a high thrombotic risk. For asymptomatic heterozygous women wishing to undergo hormone replacement therapy to control particularly severe menopausal symptoms, oral hormone replacement therapy should still be avoided.

• #55 Factor V Leiden: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/17896-factor-v-leiden

  The need (or not) to wear graded elastic compression stockings during long-haul flights and long road trips. […] Counseling prior to taking birth control pills or before becoming pregnant. […] Other than the increased risk of developing DVT or PE, factor V Leiden may increase the risk of miscarriage or other pregnancy complications, such as preeclampsia and eclampsia, placental abruption (when the placenta separates too early from the wall of your uterus), and having a fetus that grows slower than is usual. Miscarriages associated with factor V Leiden are more likely to occur later in pregnancy (after the first trimester).

• #56 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Agents/circumstances to avoid: Women with a history of VTE who are heterozygous for the factor V Leiden variant and women homozygous for the factor V Leiden variant with or without prior VTE should avoid estrogen-containing contraception and HRT. […] Pregnancy management: Women with thrombophilia should undergo individualized risk assessment. In women heterozygous for the factor V Leiden variant, antepartum prophylactic anticoagulation is not recommended for prevention of the first VTE. In homozygous and double heterozygous women (factor V Leiden and F2 20210GA variants), antepartum and postpartum prophylactic anticoagulation is suggested to prevent a first VTE. […] The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors.

• #57 Factor V Leiden: all the answers – Breda Genetics srl

  https://bredagenetics.com/factor-v-leiden-all-the-answers/

  In asymptomatic patients (i.e. who have never had an episode of venous thrombosis), long-term prophylactic anticoagulant therapy is not indicated, but only short-term therapy in the event of an exposure to circumstantial risk factors (see above). […] Women heterozygous for the Leiden variant with a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] women homozygous for the Leiden variant with or without a history of venous thromboembolism should avoid estrogen-based oral contraceptive therapy or hormone replacement therapy. […] for asymptomatic heterozygous women it would still be advisable to evaluate alternative forms of contraception or control of menopausal symptoms. However, for asymptomatic heterozygous women who still prefer oral contraceptive therapy, it would be best to avoid third generation progestogens or other types of progestogens that confer a high thrombotic risk. For asymptomatic heterozygous women wishing to undergo hormone replacement therapy to control particularly severe menopausal symptoms, oral hormone replacement therapy should still be avoided.

• #58 Factor V Leiden mutation

  https://www.aboutkidshealth.ca/factor-v-leiden-mutation

  When travelling, encourage your child to walk around whenever possible. Decreased circulation of blood flow can increase the risk for blood clots. […] Encourage your child to get regular physical activity. Children and youth typically need at least 60 minutes of moderate-to-vigorous intensity physical activity every day. […] If a child with FVL needs to take hormonal therapy (e.g., birth control pills), talk to a gynecologist about how they can be safely taken, in order to help reduce the risk of blood clots.

• #59 Is HRT Safe for People With Factor V Leiden | ParentData by Emily Osterframe_1-svgframe_2-svgframe_3-svg

  https://parentdata.org/hrt-safe-people-with-factor-v-leiden/

  Like birth control pills, hormone replacement therapy has been shown to increase the risk of blood clots for all women. […] However, the balance of risks and benefits shifts in women with a history of blood clots. Having previously had a blood clot is a contraindication to taking systemic HRT — that is, estrogen and/or progesterone as pills, gels, or patches. Vaginal estrogen is considered safe because it does not circulate in the blood at significant levels. […] One way we recommend minimizing your risk of blood clots is by avoiding birth control pills and HRT. […] It is true that women with hereditary clotting disorders like Factor V Leiden should not take systemic HRT; they can use vaginal estrogen preparations. They can also use non-hormonal treatments like Veozah to manage hot flushes, night sweats, and sleep disruption.

• #60 Is HRT Safe for People With Factor V Leiden | ParentData by Emily Osterframe_1-svgframe_2-svgframe_3-svg

  https://parentdata.org/hrt-safe-people-with-factor-v-leiden/

  Like birth control pills, hormone replacement therapy has been shown to increase the risk of blood clots for all women. […] However, the balance of risks and benefits shifts in women with a history of blood clots. Having previously had a blood clot is a contraindication to taking systemic HRT — that is, estrogen and/or progesterone as pills, gels, or patches. Vaginal estrogen is considered safe because it does not circulate in the blood at significant levels. […] One way we recommend minimizing your risk of blood clots is by avoiding birth control pills and HRT. […] It is true that women with hereditary clotting disorders like Factor V Leiden should not take systemic HRT; they can use vaginal estrogen preparations. They can also use non-hormonal treatments like Veozah to manage hot flushes, night sweats, and sleep disruption.

• #61 Factor V Leiden: Symptoms, Causes & Treatment

  https://my.clevelandclinic.org/health/diseases/17896-factor-v-leiden

  The need (or not) to wear graded elastic compression stockings during long-haul flights and long road trips. […] Counseling prior to taking birth control pills or before becoming pregnant. […] Other than the increased risk of developing DVT or PE, factor V Leiden may increase the risk of miscarriage or other pregnancy complications, such as preeclampsia and eclampsia, placental abruption (when the placenta separates too early from the wall of your uterus), and having a fetus that grows slower than is usual. Miscarriages associated with factor V Leiden are more likely to occur later in pregnancy (after the first trimester).

• #62 About Factor V Leiden Thrombophilia

  https://www.genome.gov/Genetic-Disorders/Factor-V-Leiden-Thrombophilia

  The management of individuals with factor V Leiden depends on the clinical circumstances. People with factor V Leiden who have had a DVT or PE are usually treated with blood thinners, or anticoagulants. Anticoagulants such as heparin are given for varying amounts of time depending on the person’s situation. It is not usually recommended that people with factor V Leiden be treated lifelong with anticoagulants if they have had only one DVT or PE, unless there are additional risk factors present. […] In general, individuals who have factor V Leiden but have never had a blood clot are not routinely treated with an anticoagulant. Rather, these individuals are counseled about reducing or eliminating other factors that may add to one’s risk of developing a clot in the future. In addition, these individuals may require temporary treatment with an anticoagulant during periods of particularly high risk, such as major surgery. Factor V Leiden increases the risk of developing a DVT during pregnancy by about seven-fold. Women with factor V Leiden who are planning pregnancy should discuss this with their obstetrician and/or hematologist. Most women with factor V Leiden have normal pregnancies and only require close follow-up during pregnancy. For those with a history of DVT or PE, treatment with an anticoagulant during a subsequent pregnancy can prevent recurrent problems.

• #63 About Factor V Leiden Thrombophilia

  https://www.genome.gov/Genetic-Disorders/Factor-V-Leiden-Thrombophilia

  The management of individuals with factor V Leiden depends on the clinical circumstances. People with factor V Leiden who have had a DVT or PE are usually treated with blood thinners, or anticoagulants. Anticoagulants such as heparin are given for varying amounts of time depending on the person’s situation. It is not usually recommended that people with factor V Leiden be treated lifelong with anticoagulants if they have had only one DVT or PE, unless there are additional risk factors present. […] In general, individuals who have factor V Leiden but have never had a blood clot are not routinely treated with an anticoagulant. Rather, these individuals are counseled about reducing or eliminating other factors that may add to one’s risk of developing a clot in the future. In addition, these individuals may require temporary treatment with an anticoagulant during periods of particularly high risk, such as major surgery. Factor V Leiden increases the risk of developing a DVT during pregnancy by about seven-fold. Women with factor V Leiden who are planning pregnancy should discuss this with their obstetrician and/or hematologist. Most women with factor V Leiden have normal pregnancies and only require close follow-up during pregnancy. For those with a history of DVT or PE, treatment with an anticoagulant during a subsequent pregnancy can prevent recurrent problems.

• #64 Factor V Leiden Thrombophilia – DoveMed

  https://www.dovemed.com/diseases-conditions/factor-v-leiden-thrombophilia

  Blood thinners are usually not prescribed to individuals with Factor V Leiden mutation, if they are not forming abnormal blood clots (i.e., having no symptoms). However, they may be prescribed blood thinners prophylactically, in situations such as elective major surgery, prolonged immobilization, and during other conditions. […] During pregnancy, most women with Factor V Leiden have uneventful normal pregnancies. However, these individuals are at increased risk of developing blood clots. Hence, such individuals should be closely monitored by their healthcare provider during the pregnancy term.

• #65 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Agents/circumstances to avoid: Women with a history of VTE who are heterozygous for the factor V Leiden variant and women homozygous for the factor V Leiden variant with or without prior VTE should avoid estrogen-containing contraception and HRT. […] Pregnancy management: Women with thrombophilia should undergo individualized risk assessment. In women heterozygous for the factor V Leiden variant, antepartum prophylactic anticoagulation is not recommended for prevention of the first VTE. In homozygous and double heterozygous women (factor V Leiden and F2 20210GA variants), antepartum and postpartum prophylactic anticoagulation is suggested to prevent a first VTE. […] The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors.

• #66 Thrombophilias in Pregnancy Treatment & Management: Approach Considerations, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/2056429-treatment

  The following recommendations are based on the table from ACOG Practice Bulletin 123, Published September 2011 (reaffirmed in 2014): […] High-risk thrombophilia (antithrombin deficiency, homozygous factor V Leiden, homozygous prothrombin mutation G20210A, double heterozygous factor V Leiden and prothrombin mutation G20210A) without prior VTE: Prophylactic LMWH or UFH […] Anticoagulation therapy. […] A systematic review by Croles et al reported that antepartum or postpartum thrombosis prophylaxis, or both should be considered for women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden. […] For patients who meet the criteria for obstetric antiphospholipid syndrome, the American College of Rheumatology (ACR) strongly recommends combined lowdose aspirin and prophylacticdose heparin (usually LMWH). The ACR strongly recommends continuing prophylacticdose anticoagulation for 6-12 weeks postpartum. […] Because data on the maternal and fetal safety of direct oral anticoagulants (DOACs) are scant, these agents are generally avoided in pregnancy.

• #67 LCD – MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (L36155)

  https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36155

  For all pregnant women with prior VTE, we suggest postpartum prophylaxis for 6 weeks with prophylactic or intermediate dose LMWH or VKAs targeted at INR 2.0 to 3.0 rather than no prophylaxis; […] For pregnant women at moderate to high risk of recurrent VTE (single unprovoked VTE, pregnancy or estrogen related VTE, or multiple prior unprovoked VTE not receiving long term anticoagulation), we suggest antepartum prophylaxis with prophylactic or intermediate dose LMWH rather than clinical vigilance or routine care. […] Genetic testing for these patients is indicated. There may also be benefit to screening pregnant women with a family history of known thrombophilia, as those women found to have a high risk genotype would be offered antenatal prophylactic anticoagulant therapy even in the absence of a personal history of VTE.

• #68 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Agents/circumstances to avoid: Women with a history of VTE who are heterozygous for the factor V Leiden variant and women homozygous for the factor V Leiden variant with or without prior VTE should avoid estrogen-containing contraception and HRT. […] Pregnancy management: Women with thrombophilia should undergo individualized risk assessment. In women heterozygous for the factor V Leiden variant, antepartum prophylactic anticoagulation is not recommended for prevention of the first VTE. In homozygous and double heterozygous women (factor V Leiden and F2 20210GA variants), antepartum and postpartum prophylactic anticoagulation is suggested to prevent a first VTE. […] The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. Recurrence risk is determined by the clinical circumstances of the first event (provoked or unprovoked), adequacy of early treatment, and individual risk factors.

• #69 Thrombophilias in Pregnancy Treatment & Management: Approach Considerations, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/2056429-treatment

  The following recommendations are based on the table from ACOG Practice Bulletin 123, Published September 2011 (reaffirmed in 2014): […] High-risk thrombophilia (antithrombin deficiency, homozygous factor V Leiden, homozygous prothrombin mutation G20210A, double heterozygous factor V Leiden and prothrombin mutation G20210A) without prior VTE: Prophylactic LMWH or UFH […] Anticoagulation therapy. […] A systematic review by Croles et al reported that antepartum or postpartum thrombosis prophylaxis, or both should be considered for women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden. […] For patients who meet the criteria for obstetric antiphospholipid syndrome, the American College of Rheumatology (ACR) strongly recommends combined lowdose aspirin and prophylacticdose heparin (usually LMWH). The ACR strongly recommends continuing prophylacticdose anticoagulation for 6-12 weeks postpartum. […] Because data on the maternal and fetal safety of direct oral anticoagulants (DOACs) are scant, these agents are generally avoided in pregnancy.

• #70 LCD – MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (L36155)

  https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=36155

  For all pregnant women with prior VTE, we suggest postpartum prophylaxis for 6 weeks with prophylactic or intermediate dose LMWH or VKAs targeted at INR 2.0 to 3.0 rather than no prophylaxis; […] For pregnant women at moderate to high risk of recurrent VTE (single unprovoked VTE, pregnancy or estrogen related VTE, or multiple prior unprovoked VTE not receiving long term anticoagulation), we suggest antepartum prophylaxis with prophylactic or intermediate dose LMWH rather than clinical vigilance or routine care. […] Genetic testing for these patients is indicated. There may also be benefit to screening pregnant women with a family history of known thrombophilia, as those women found to have a high risk genotype would be offered antenatal prophylactic anticoagulant therapy even in the absence of a personal history of VTE.

• #71 About Factor V Leiden Thrombophilia

  https://www.genome.gov/Genetic-Disorders/Factor-V-Leiden-Thrombophilia

  The management of individuals with factor V Leiden depends on the clinical circumstances. People with factor V Leiden who have had a DVT or PE are usually treated with blood thinners, or anticoagulants. Anticoagulants such as heparin are given for varying amounts of time depending on the person’s situation. It is not usually recommended that people with factor V Leiden be treated lifelong with anticoagulants if they have had only one DVT or PE, unless there are additional risk factors present. […] In general, individuals who have factor V Leiden but have never had a blood clot are not routinely treated with an anticoagulant. Rather, these individuals are counseled about reducing or eliminating other factors that may add to one’s risk of developing a clot in the future. In addition, these individuals may require temporary treatment with an anticoagulant during periods of particularly high risk, such as major surgery. Factor V Leiden increases the risk of developing a DVT during pregnancy by about seven-fold. Women with factor V Leiden who are planning pregnancy should discuss this with their obstetrician and/or hematologist. Most women with factor V Leiden have normal pregnancies and only require close follow-up during pregnancy. For those with a history of DVT or PE, treatment with an anticoagulant during a subsequent pregnancy can prevent recurrent problems.

• #72 Factor V Leiden – Blood Clots

  https://www.stoptheclot.org/learn_more/factor-v-leiden-2/

  Having factor V Leiden means that you have a greater chance of developing a dangerous blood clot in your legs (DVT) or lungs (PE). […] There is no treatment that can prevent this disorder or make it go away. However, there are things that you can do to reduce your chances of developing a dangerous blood clot. […] You do need treatment with blood thinners if you have had a blood clot or develop one in the future. These medications (called anticoagulants) help to prevent clotting. If you have never had a blood clot, you do not need treatment with blood thinners. […] In situations where there is a greater chance of clotting (such as surgery, a leg cast, a serious illness or pregnancy) you may be treated with blood thinners until the risk has passed. […] Women have a greater chance of developing a blood clot during pregnancy. Before becoming pregnant, talk with your doctor about how your risk of blood clots can be managed during pregnancy, childbirth and for six weeks postpartum. You may be treated with blood thinners during this time.

• #73 Thrombophilias in Pregnancy Treatment & Management: Approach Considerations, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/2056429-treatment

  The following recommendations are based on the table from ACOG Practice Bulletin 123, Published September 2011 (reaffirmed in 2014): […] High-risk thrombophilia (antithrombin deficiency, homozygous factor V Leiden, homozygous prothrombin mutation G20210A, double heterozygous factor V Leiden and prothrombin mutation G20210A) without prior VTE: Prophylactic LMWH or UFH […] Anticoagulation therapy. […] A systematic review by Croles et al reported that antepartum or postpartum thrombosis prophylaxis, or both should be considered for women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden. […] For patients who meet the criteria for obstetric antiphospholipid syndrome, the American College of Rheumatology (ACR) strongly recommends combined lowdose aspirin and prophylacticdose heparin (usually LMWH). The ACR strongly recommends continuing prophylacticdose anticoagulation for 6-12 weeks postpartum. […] Because data on the maternal and fetal safety of direct oral anticoagulants (DOACs) are scant, these agents are generally avoided in pregnancy.

• #74 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Indefinite anticoagulation is recommended for individuals with a first or recurrent unprovoked proximal DVT of the leg and a high risk of recurrence due to risk factors such as cancer, combined thrombophilia, or homozygosity for the factor V Leiden variant. […] Treatment of VTE in Children: The treatment of acute VTE is not influenced by identification of a factor V Leiden variant. Children with a first VTE should receive initial treatment with either unfractionated heparin or LMWH for at least five days. […] In children with a factor V Leiden variant, the duration of anticoagulation following VTE may include indefinite anticoagulation or intermittent anticoagulation in high-risk situations after considering the risk of side effects of anticoagulation (e.g., major bleeding), the risk of recurrent VTE, and the preference of the affected individual.

• #75 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Indefinite anticoagulation is recommended for individuals with a first or recurrent unprovoked proximal DVT of the leg and a high risk of recurrence due to risk factors such as cancer, combined thrombophilia, or homozygosity for the factor V Leiden variant. […] Treatment of VTE in Children: The treatment of acute VTE is not influenced by identification of a factor V Leiden variant. Children with a first VTE should receive initial treatment with either unfractionated heparin or LMWH for at least five days. […] In children with a factor V Leiden variant, the duration of anticoagulation following VTE may include indefinite anticoagulation or intermittent anticoagulation in high-risk situations after considering the risk of side effects of anticoagulation (e.g., major bleeding), the risk of recurrent VTE, and the preference of the affected individual.

• #76 Factor V Deficiency Treatment & Management: Medical Care, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/209492-treatment

  Although a plasma-derived factor V concentrate is undergoing preliminary testing, no concentrates of factor V are commercially available. Instead, fresh plasma or fresh frozen plasma (FFP, Octaplas) infusions are used to correct the deficiency temporarily and should be given daily during a bleeding episode. The loading dose of FFP is 15-20 mL/kg and then 3-6 mL/kg daily. Subsequent dosages depend on monitoring the factor V level by obtaining peak and trough factor V level assays. The half-life ranges from 24-36 hours, with the aim being a factor V level of 25%. Fluid overload and viral transmission may be a complication of plasma therapy. […] Alternatively, platelet transfusions are emerging as an alternative to FFP. Factor V stored within platelet alpha granules has greater procoagulant potential and is released locally at sites of vascular injury.

• #77 Factor V deficiency | Great Ormond Street Hospital

  https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/factor-v-deficiency/

  For mildly affected children whose symptoms are not problematic, regular treatment may not be needed. Instead, they will receive treatment on demand basis to treat symptoms as they occur. […] Children with severe Factor V deficiency will need to start regular preventative (prophylaxis) treatment to prevent severe bleeding. […] Treatment may also be required as part of planning for an operation or treating an injury. […] Unlike other factors, Factor V is not available in a separate replacement form, so an infusion of fresh frozen plasma (FFP) is usually given instead. […] For minor symptoms, a medicine called tranexamic acid can be given instead, to temporarily boost the proteins that stabilise blood clots. […] Females may have to take additional measures to make their monthly periods manageable. Options can include taking tranexamic acid before and during her periods and hormonal methods such as the contraceptive pill.

• #78 Factor V Deficiency | Symptoms, Genetics, Treatment | NBDF

  https://www.bleeding.org/bleeding-disorders-a-z/types/other-factor-deficiencies/factor-v

  Fresh frozen plasma (FFP) is the only treatment available, as no commercially available factor V concentrate exists. […] In acute cases of severe bleeding, the addition of platelet concentrates may be needed. […] Solvent-detergent FFP may contain a more reliable level of FV than standard FFP. […] Treatment includes fresh frozen plasma. In some cases, bleeds may be treated with FVIII concentrates and desmopressin acetate, the synthetic version of the hormone vasopressin.

• #79 Factor V Deficiency Treatment & Management: Medical Care, Consultations, Long-Term Monitoring

  https://emedicine.medscape.com/article/209492-treatment

  Although a plasma-derived factor V concentrate is undergoing preliminary testing, no concentrates of factor V are commercially available. Instead, fresh plasma or fresh frozen plasma (FFP, Octaplas) infusions are used to correct the deficiency temporarily and should be given daily during a bleeding episode. The loading dose of FFP is 15-20 mL/kg and then 3-6 mL/kg daily. Subsequent dosages depend on monitoring the factor V level by obtaining peak and trough factor V level assays. The half-life ranges from 24-36 hours, with the aim being a factor V level of 25%. Fluid overload and viral transmission may be a complication of plasma therapy. […] Alternatively, platelet transfusions are emerging as an alternative to FFP. Factor V stored within platelet alpha granules has greater procoagulant potential and is released locally at sites of vascular injury.

• #80 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Long-term management of patients with inherited thrombophilia had not been well studied. […] Current medications include Heparin: works more quickly than warfarin does and is safe in pregnancy, but must be monitored closely due to the risk of excess bleeding. […] Management of factor V Leiden continues to be a challenge due to the fact that the current treatment regimen has not been able to effectively provide treatment without adverse effects. […] We remain hopeful that there will be continued research in this area and that newer and emerging treatments will help balance the risks and help us manage our patients more effectively.

• #81 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149

  Factor V Leiden is a genetically inherited disorder which causes hypercoagulable state that accounts for 40-50% of cases of thrombophilia. […] Management of this disorder can be challenging due to the fact that the current treatment regimen can place the patient in a bleeding state with potential hazardous effects. […] a 49-year-old man who presented with shortness of breath diagnosed with multiple episodes of pulmonary embolisms, DVT and factor V Leiden deficiency treated with oral anticoagulants again presented with dizziness and upper GI bleed.

• #82 Treatment for Factor V Leiden, Stuck Between a Rock and a Hard Place: A Case Report and Review of Literature | Jehangir | Journal of Hematology

  https://thejh.org/index.php/jh/article/view/149/103

  Long-term management of patients with inherited thrombophilia had not been well studied. […] Current medications include Heparin: works more quickly than warfarin does and is safe in pregnancy, but must be monitored closely due to the risk of excess bleeding. […] Management of factor V Leiden continues to be a challenge due to the fact that the current treatment regimen has not been able to effectively provide treatment without adverse effects. […] We remain hopeful that there will be continued research in this area and that newer and emerging treatments will help balance the risks and help us manage our patients more effectively.

• #83 Factor V Leiden Thrombophilia – DoveMed

  https://www.dovemed.com/diseases-conditions/factor-v-leiden-thrombophilia

  The usual treatment options for abnormal clot formation are the use of anticoagulants such as heparin, warfarin, rivaroxaban, etc. […] Blood thinning medicines are generally administered to treat individuals with active abnormal blood clot formation. The treatment options include: Heparin (or low molecular weight heparin), administered through the vein, or under the skin; Warfarin (oral medication) may also be given, except during pregnancy, as it may cause birth defects; Generally, the initial treatment given is a combination of warfarin and heparin, followed by warfarin alone; Other medications that may be given include enoxaparin, dalteparin, dabigatran, and rivaroxaban. […] When an individual is taking anticoagulant medication, he/she should be monitored for side effects (bleeding) by the healthcare provider including by using periodic blood tests.

• #84 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Treatment of manifestations: The first acute venous thrombosis is treated according to current guidelines. The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. […] Prevention of primary manifestations: In the absence of a history of thrombosis, long-term prophylactic anticoagulation is not routinely recommended for asymptomatic factor V Leiden variant heterozygotes. A short course of prophylactic anticoagulation when transient risk factors are present may prevent initial thrombosis in heterozygotes. […] Surveillance: Periodic reevaluation of individuals on long-term anticoagulation to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.

• #85 Factor V Leiden Thrombophilia – GeneReviews® – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK1368/

  Treatment of manifestations: The first acute venous thrombosis is treated according to current guidelines. The duration of oral anticoagulation therapy should be based on an assessment of the risks for VTE recurrence and anticoagulant-related bleeding. […] Prevention of primary manifestations: In the absence of a history of thrombosis, long-term prophylactic anticoagulation is not routinely recommended for asymptomatic factor V Leiden variant heterozygotes. A short course of prophylactic anticoagulation when transient risk factors are present may prevent initial thrombosis in heterozygotes. […] Surveillance: Periodic reevaluation of individuals on long-term anticoagulation to confirm that the benefits of anticoagulation continue to outweigh the risk of bleeding. Factor V Leiden heterozygotes who do not require long-term anticoagulation may benefit from evaluation prior to exposure to circumstantial risk factors such as surgery or pregnancy.

• #86 Factor V Leiden | CommonSpirit Health

  https://www.commonspirit.org/conditions-treatments/factor-v-leiden

  Take your medicines exactly as prescribed. Call your doctor if you think you are having a problem with your medicine. […] If you take a blood thinner, be sure you get instructions about how to take your medicine safely. Blood thinners can cause serious bleeding problems. […] Check with your doctor about whether you should use hormone forms of birth control or hormone therapy. These may increase your risk of blood clots. […] Do not smoke. It can increase the risk of blood clots. If you need help quitting, talk to your doctor about stop-smoking programs and medicines. These can increase your chances of quitting for good. […] Call your doctor now or seek immediate medical care if: […] Watch closely for changes in your health, and be sure to contact your doctor if you have any problems.

• #87 Factor V Leiden – American Blood Clot Association

  https://bloodclot.org/factor-v-leiden/

  It is important to note that treatment for Factor V Leiden should be tailored to each individual’s specific needs. […] Your healthcare provider will evaluate your unique circumstances and develop a comprehensive treatment plan to help reduce the risk of blood clots and manage the condition effectively. […] Diagnosing Factor V Leiden involves a combination of medical history evaluation, physical examination, and laboratory tests. […] The definitive test for Factor V Leiden is a genetic test, which involves analyzing a sample of blood or saliva for the specific genetic mutation.

• #88 Treating Factor V Leiden: What Are Your Options? – Doctronic, Your Trusted AI Doctor

  https://www.doctronic.ai/conditions-diseases/treating-factor-v-leiden-what-are-your-options-MFKFML

  Factor V Leiden increases the risk of blood clots, but various treatments can help manage and reduce this risk. […] For individuals with blood clots, initial treatment often involves anticoagulants like warfarin or direct oral anticoagulants (DOACs). These drugs help prevent new clots and stop existing ones from growing. Treatment is tailored based on the severity of the clot and individual health needs. […] Deciding on long-term therapy depends on the risk of recurrent clots. Factors include the nature of the first clot and personal health history. Some may need extended anticoagulation, especially after a life-threatening event or recurrent clots. […] Asymptomatic people with Factor V Leiden often don’t require treatment unless they face high-risk situations. It’s crucial to consult with healthcare providers to make informed decisions, especially when considering surgery, pregnancy, or contraception. […] Effective management of Factor V Leiden involves understanding and choosing the right treatment options.

Zobacz więcej